Intercept Pharmaceuticals Stock Forecast, Price & News

+0.37 (+2.19 %)
(As of 07/29/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume754,924 shs
Average Volume989,718 shs
Market Capitalization$571.71 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ICPT News and Ratings via Email

Sign-up to receive the latest news and ratings for Intercept Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Intercept Pharmaceuticals logo

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and other product candidates in various stages of clinical and preclinical development. It has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in New York, New York.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.21 out of 5 stars

Medical Sector

111th out of 2,214 stocks

Pharmaceutical Preparations Industry

52nd out of 869 stocks

Analyst Opinion: 4.1Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions

Is Intercept Pharmaceuticals a buy right now?

20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last year. There are currently 1 sell rating, 13 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Intercept Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICPT, but not buy additional shares or sell existing shares.
View analyst ratings for Intercept Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Intercept Pharmaceuticals?

Wall Street analysts have given Intercept Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Intercept Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) issued its earnings results on Thursday, July, 29th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.24) by $0.91.
View Intercept Pharmaceuticals' earnings history

How has Intercept Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Intercept Pharmaceuticals' stock was trading at $77.60 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ICPT shares have decreased by 77.8% and is now trading at $17.24.
View which stocks have been most impacted by COVID-19

What guidance has Intercept Pharmaceuticals issued on next quarter's earnings?

Intercept Pharmaceuticals updated its FY 2021 earnings guidance on Thursday, July, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $325 million-$340 million, compared to the consensus revenue estimate of $334.31 million.

What price target have analysts set for ICPT?

20 equities research analysts have issued 1 year target prices for Intercept Pharmaceuticals' stock. Their forecasts range from $16.00 to $88.00. On average, they expect Intercept Pharmaceuticals' stock price to reach $37.95 in the next twelve months. This suggests a possible upside of 120.1% from the stock's current price.
View analysts' price targets for Intercept Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Intercept Pharmaceuticals' key executives?

Intercept Pharmaceuticals' management team includes the following people:
  • Mr. Jerome B. Durso, Pres, CEO & Director (Age 53, Pay $853.17k)
  • Dr. Mark Pruzanski, Founder, Advisor & Director (Age 53, Pay $1.3M)
  • Mr. Andrew Saik, Chief Financial Officer (Age 52)
  • Mr. Rocco Venezia, Chief Accounting Officer & Treasurer
  • Ms. Lisa M. DeFrancesco, Sr. VP of Corp. Affairs & Investor Relations (Age 42)
  • Mr. Jared M. Freedberg, Gen. Counsel (Age 52)
  • Mr. David Ford, Chief HR Officer (Age 51)
  • Dr. Gail Cawkwell, Sr. VP of Medical Affairs, Safety & Pharmacovigilance and Acting Chief Medical Officer (Age 58)
  • Ms. Linda M. Richardson, Exec. VP & Chief Commercial Officer (Age 57)
  • Mr. Bryan Ball, Chief Quality Officer (Age 51)

What is Mark Pruzanski's approval rating as Intercept Pharmaceuticals' CEO?

32 employees have rated Intercept Pharmaceuticals CEO Mark Pruzanski on Mark Pruzanski has an approval rating of 80% among Intercept Pharmaceuticals' employees.

Who are some of Intercept Pharmaceuticals' key competitors?

What other stocks do shareholders of Intercept Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib).

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

How do I buy shares of Intercept Pharmaceuticals?

Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intercept Pharmaceuticals' stock price today?

One share of ICPT stock can currently be purchased for approximately $17.24.

How much money does Intercept Pharmaceuticals make?

Intercept Pharmaceuticals has a market capitalization of $571.71 million and generates $312.69 million in revenue each year. The biopharmaceutical company earns $-274,880,000.00 in net income (profit) each year or ($8.34) on an earnings per share basis.

How many employees does Intercept Pharmaceuticals have?

Intercept Pharmaceuticals employs 498 workers across the globe.

What is Intercept Pharmaceuticals' official website?

The official website for Intercept Pharmaceuticals is

Where are Intercept Pharmaceuticals' headquarters?

Intercept Pharmaceuticals is headquartered at 10 Hudson Yards 37th FL, New York NY, 10001.

How can I contact Intercept Pharmaceuticals?

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]

This page was last updated on 7/30/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.